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Abstract 
 
  N-methyl-D-asparate (NMDA) receptors located within the basolateral complex of the 
amygdala are required for the consolidation and expression of Pavlovian conditioned 
fear. The events downstream of receptor activation that mediate these processes are 
not well defined. An intermediate step that may be of significance is the synthesis of 
the gas nitric oxide (NO). Nitric oxide is synthesised as a result of NMDA receptor 
activation and acts as an unconventional neurotransmitter freely diffusing across cell 
membranes interacting with its targets in a non-synaptic manner. The targets of NO 
include cellular components that play significant roles during the consolidation of 
conditioned fear and the neurotransmission associated with its expression. This 
implies that NO may be an important intermediary of NMDA receptor activation and 
both these processes. The current study sought to examine this possibility using fear 
potentiated startle to examine the expression of learned fear. Three experiments were 
conducted, fifty rats received intra-BSC microinfusions of the global nitric oxide 
synthase inhibitor L-NAME either prior to fear conditioning, fear testing, or 
examination of the shock sensitization of the acoustic startle affect. The results 
indicated that NO was indeed required for both the consolidation and expression of 
learned fear, whereas it was not required for shock enhanced startle responding. This 
study provides new information about the sub-cellular basis of conditioned fear, and 
highlights the pivotal role played by NO in processes associated with conditioned 
fear.  
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1. Introduction 
1.1 General introduction 
 
Fear is one of the most intense emotions that an individual can experience. From an 
evolutionary perspective, fear is extremely important as it can deter an individual from 
situations and stimuli that could be dangerous. The strength of the emotion, specifically, its 
ability to strongly regulate behaviour, makes it adaptive. However, fear can be a double-
edged sword. It can also be irrepressible, playing roles in psychological disturbances such as 
post-traumatic-stress disorder; anxiety related disorders; and many phobias. A detailed 
understanding of the molecular and cellular underpinnings of fear would, in turn, provide 
insight into the possible neuroanatomical basis of such emotional psychopathology.  
 The amygdala is a temporal lobe structure intimately involved in fear processing. 
More specifically, it links the perception of aversive stimuli with the neuroanatomy that 
regulates the behavioural and autonomical processes associated with fear responding. 
Furthermore, it plays the most predominate role in neuroanatomical underpinnings of fear 
memory formation, specifically Pavlovian conditioned fear. The fact that the amygdala plays 
a role in fear conditioning is well established. Research concerning fear memory formation is 
currently focussing on the cellular and sub-cellular events in the amygdala that mediate 
processing associated with learned fear.  
Research has shown that amygdaloid N-methyl-D-asparate (NMDA) receptors play a 
crucial role in both the consolidation and expression of learned fear (Bauer, 2000; Campeau, 
1992; Fendt, 2001; Goosens, 2004; Lee, 2001; Maren, 1996; Miserendino, 1990; Rodrigues, 
2004; Walker, 2000, 2002). However, a detailed understanding of the events downstream of 
receptor activation that mediate these processes is lacking. A significant event could be the 
synthesis of the gas nitric oxide (NO). NO is second messenger that is ultimately synthesised 
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by calcium that passes through the activated NMDA receptor channel. It freely diffuses 
across cell membranes where it can directly interact with a large number of targets, and set in 
motion numerous signal transduction pathways. Many of the targets of NO, or the 
consequences of its signalling, are involved in both the consolidation and expression of 
learned fear. Thus, NO signalling may be a significant mediatory of NMDA receptor 
activation and these processes.  
Thus, the main aim of this study was to determine whether NO signalling is required for 
processes association with conditioned fear. More specifically, the significance of NO 
synthesis during fear memory consolidation, the expression of learned fear, and the 
expression of unconditioned fear was examined. No previous study has analysed whether NO 
could play a role during these processes, specifically when a light is used as a conditioned 
stimulus and fear potentiated startle is used to examine the expression of learned fear.  
Below, to assist in understanding how NO could modulate process associated with 
learned fear, the literature concerning the structure and function of the amygdala are 
discussed in section 1.4, followed by an overview of the neurochemical and cellular 
processes associated with fear memory consolidation and expression in sections 1.5 through 
to 1.7. This includes an overview of the role of the NMDA receptor in conditioned fear in 
section 1.7.2. Section 1.8 concerns how NO could affect the expression and consolidation of 
learned fear. Finally sections 1.9 and 1.10 detail the importance of this research and the 
experimental procedures employed in this current study. Firstly, however the historical 
background concerning the role of the amygdala in emotional possessing is presented.   
  
4 
1.2 Historical background  
 
Research suggesting that the amygdala may play a role in emotion originated some 60 
year ago. Kluver and Bucy (1939) reported that temporal lobe lesions in primates caused 
extreme changes in emotional behaviour (cited in Weiskrantz, 1956). They reported, amongst 
other deficits, that visual stimuli and events appeared to lose their emotional value. For 
example, the animals tried to eat uneatable objects; copulate with animals of the same sex; 
and lost their fear of snakes and humans. Kluver and Bucy (1939) referred to this as psychic 
blindness. Today psychopathology in humans resulting from temporal lobe damage of a 
comparable magnitude is often referred to as the Kluver Bucy syndrome. Most importantly, 
this innovative research revealed that the temporal lobe is a key brain area involved in 
processing emotion. However, the lesions inflicted in the primates were large and 
encompassed many anatomically distinct structures including the amygdala, hippocampus, 
and surrounding cortical areas. The precise details regarding the neuroanatomical 
underpinnings of the behavioural deficits were consequently lacking.   
Weiskrantz (1956) subsequently discovered that damage to the amygdala was the 
primary cause of the Kluver Bucy syndrome. He reported that primates with bilateral 
amygdalectomies exhibited behaviour abnormalities consistent with those reported by Kluver 
and Bucy (1939) after more sizeable lesions of the temporal lobe. Weiskrantz (1956) also 
went a step further and experimentally analysed the behavioural change associated with 
amygdaloid damage. He demonstrated that the amygdala is crucial for avoidance 
conditioning, a process in which an animal learns to avoid a fearful stimulus, such as a shock, 
by performing a particular response. Based on this, Weiskrantz proposed that the amygdala 
was necessary for making the association between objects or events and their emotional 
consequence. Research concerning exactly how the amygdala underpins this and other 
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behavioural processes proliferated during the years that followed. It appears that the 
amygdala also plays a role in events including attention, object reward associations, and 
social behaviour (Alexander, 2000; Bachevalier, 2000; Compton, 2003). Notwithstanding the 
complexity of amygdaloid functioning and consistent with Weiskrantz’s proposal, most of the 
research regarding the amygdala has concerned how it imbues an event or stimulus with 
emotion, especially fear. One of the most predominant and reliable methods used to examine 
this is Pavlovian fear conditioning.  
1.2.1 Pavlovian fear conditioning  
 
During the fear conditioning procedure an animal, usually a rat, is presented with 
contiguous pairings of an emotionally neutral conditioned stimulus (CS), such as a light or a 
tone, and an innately feared unconditioned stimulus (US), most often a footshock. The animal 
consequently learns to fear the CS because it associates it with the US. That is, the CS 
acquires the emotional value of the US. Subsequent presentation of the CS produces a fear 
response equivalent to that formerly only provoked by the US.  The most common laboratory 
measures used to ascertain whether the animal has indeed learnt the association are CS-
induced freezing and fear potentiated startle (FPS) (LeDoux, 2000). Defensive freezing is an 
adaptive response of small animals characterised by complete immobilization of all 
movement except for that required for normal respiration. FPS, on the other hand, is 
characterised by a fast sequential muscle contraction in response to a sudden stimulus that is 
augmented in the presence of the CS. Generally, freezing is used to assess fear when the CS 
is auditory, while increased reflex potential is used when the CS is visual, most commonly a 
light. Both light and tone are discrete cues and have been used extensively in fear 
conditioning research. It is noteworthy, however, that the context in which the US is 
presented can also serve as a CS. In this case the CS is not discrete; it is instead comprised of 
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the features that make up the environment including the smell, size, illumination, and other 
salient cues observable by the animal. This current study concerns conditioning involving 
discrete cues, consequently such research where freezing and FPS have been employed to 
measure fear will be discussed below. Research involving discrete cues, and complementary 
in vitro studies, have provided a wealth of information concerning how the amygdala 
mediates fear processing. The discussion below will begin with the amygdala’s place at a 
systems level within the fear circuitry, its neuroanatomy, and its neurophysiology.  
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1.3. The Neuroanatomy of the amygdala  
 
The general composition of the amygdala is now quite well characterised. It is an 
almond shaped multinuclear structure located within the medial edge of the temporal lobe. It 
is comprised of 13 diverse nuclei and cortical regions, which are often further divided into 
two or more subdivisions (McDonald, 1998; Pitkanen, 2000; Sah, 2003). These richly 
interconnected structures are grouped according to their electrophysiological properties, 
cytoarchitecture, histochemistry, and their extrinsic and intrinsic nuclear connections. 
Research from lesion, pharmacological, stimulation, and recording studies have indicated that 
both the basolateral complex (BSC) and the central nucleus (CE) of the amygdala play crucial 
roles in the neuroanatomical and neurophysiological underpinnings of conditioned fear (for a 
review see Kim, 2005). Essentially, together they form the interface between stimulus 
processing and the psychological and physiological characteristics of a fear response. 
1.3.1 The Basolateral complex  
 
Tract tracing studies have revealed that the BSC is the preponderate area of sensory 
input, receiving extensive excitatory afferents from sensory and higher order processing areas 
(Pitkanen, 1997). Essentially, sensory information concerning conditioned fear travels via the 
thalamus before reaching the BSC. From this point it can either journey directly to the BSC, 
or it can travel indirectly to the complex via higher order cortical areas (Davis, 1994; Doron, 
1999; Lanuza, 2004; Shi, 1999a, 2001b). The BSC is composed of the lateral (LA), basal 
lateral (BL), and the basal medial (BM) nuclei. Incoming sensory information enters at 
different nuclei depending on its origin. The LA predominantly receives CS and US sensory 
information directly from the thalamus, while  the BL and BM, primarily receive information 
from internal or higher order processing areas such as the hippocampus, hypothalamus, 
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perirhinal cortex, and other secondary and polymodal cortical areas (Davis, 1994; Doron, 
1999; Lanuza, 2004; Pitkanen, 1997; Shi, 1999a, 2001b). All forms of excitatory 
neurotransmission, however, is modulated, integrated, and processed within the complex by 
each nucleus (Pitkanen, 1997). Thus, the BSC acts as the primary interface of the amygdala 
by processing incoming sensory information. When sensory information is deemed to be 
fearful the neurotransmission that it provokes in the BSC ultimately excites cells in the CE 
(Pitkanen, 1997).  
1.3.2 Afferents of the Central Nucleus  
 
The CE, which is subdivided into capsular, lateral, intermediate, and medial divisions, 
is the major output component of the amygdala. During neuronal activity associated with 
learned fear it is excited by the neurotransmission that originates from the BSC. It must be 
noted, however, that the CE also receives excitatory efferents from visual, auditory, and 
somatosensory areas via structures such as the posterior thalamic nucleus and parabrachial 
pathways (Lanuza, 2004). Nonetheless, projections from the BSC play an important role in 
conditioned fear, especially when the CS is discrete rather than contextual (Koo, 2004). Tract 
tracing studies have revealed that projections from the BL and BM predominantly target the 
medial portion of the CE. The only other component that receives BSC projections is the 
lateral CE, however its afferents are light (Maren, 1999; Pare, 1995). The LA, on the other 
hand, does not project directly to the CE. Output projections from the LA synapse onto a net 
of interconnected GABAergic cell clusters situated in between the BSC and CE, which are 
referred to as the intercalated cell masses. These cells, in turn, project to the medial portion of 
the CE (Millhouse, 1986; Pare, 1993; Royer, 1999). Research by Royer and colleagues 
(1999) has revealed that the intercalated cells tonically inhibit excitatory activity in the 
medial portion of the CE, and consequently gate information flow between the LA and CE. 
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During the initiation of a fear response excitation in the LA alleviates the inhibition imposed 
by the intercalated cells; this as well as direct projections from the BL and BM increases 
cellular excitation in the medial portion of the CE (Royer, 1999).  
1.3.3 Efferents of the Central Nucleus 
 
The medial portion of the CE is dense with spiny excitatory projection neurons, these 
synapses onto a number of brain stem and hypothalamic regions that mediate the autonomic 
and behavioural characteristics of a fear response (for a review see Davis, 2000a). For 
example, projections to the lateral hypothalamus mediate the autonomic characteristics of 
fear, such as increased blood pressure and pupil dilation (LeDoux, 1988). Projections to the 
paraventricular nucleus of the hypothalamus regulate the activation of the hypothalamo-
pituitary-adrenocortical axis, which is intimately involved in mediating a general stress 
response (Herman, 2004). Efferents to the midbrain central grey and the reticularis pontis 
caudalis regulate freezing and FPS respectively, both of which, as mentioned, are 
predominantly used to assess fear learning. Finally, efferents to mid brain areas such as the 
ventral tegmental area (VTA) and the locus coeruleus (LC) initiate the release of excitatory 
catecholamines. These neurotransmitters act as neuronal modulators, enhancing excitation in 
various brain areas including the amygdala. Accordingly, their influence on conditioned fear 
is discussed in more detail below. Thus, the CE is the output component of the amygdala, 
activating brain regions that regulate the autonomic and behavioural characteristics of a fear 
response. The fear response is, in turn, characterised by a general increase in arousal in both 
the central and peripheral nervous system.  
Thus, the CE mediates a fear response, while the BSC is the sensory interface of the 
amygdala. Because the BSC, especially the lateral component of the complex, processes CS 
and US associated sensory information it is the neuroanatomical location that plays the most 
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predominant role in the varying aspects of fear conditioning. Processes that occur within the 
BSC associated with fear memory will consequently dominate the rest of the introduction. 
Manipulation of the neurochemistry within this complex during either fear conditioning or 
expression has shed light on the chemical modulation of the complex associated with learned 
fear. 
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1.4 Neurochemistry of conditioned fear 
 
Many neurochemical influences of BSC functioning have been described. However, 
only those applicable to this current study, specifically γ-aminobutyric acid (GABA), 
glutamate, and the catecholamines, will be discussed below. 
1.4.1 GABA 
 
 In the resting BSC GABA is found at a high concentration in the extracellular fluid; 
as a result it imposes a global blanket of inhibition on the structure. This is predominantly 
mediated by the ionotropic GABAA receptor (Millan, 2003). Activation of the receptor results 
in an influx of negative chloride ions into the cell, hyperpolarizing the cell membrane and 
impeding cellular excitation. Accordingly, stimulation of amygdaloid GABAA receptors 
obstructs fear processing. For example, infusing the GABAA receptor agonist muscimole into 
the amygdala immediately prior to either fear conditioning or testing significantly attenuates 
both processes (Muller, 1997). Thus, for any aspect of conditioned fear processing to take 
place the global blanket of inhibition imposed by GABA must subside. Indeed, the 
extracellular concentration of GABA declines upon presentation of the CS is conditioned 
animals (Stork, 2002). Thus, GABA inhibits excitatory neurotransmission in the BSC. During 
conditioned fear associated processes this inhibitory influence is alleviated, consequently 
permitting excitatory neurotransmission.  
1.4.2 Glutamate  
 
Glutamatergic neurotransmission is the principle means of excitatory communication 
both within the BSC as well as from sensory areas to the complex (Walker, 2002). This is, in 
turn, mediated by a number of different glutamate receptors. However, only the activity of 
the L-α-amino-3-hydroxy-5-mrthyl-4-isoxazole propionate (AMPA) and NMDA receptors 
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relates to this current study and will be discussed below. AMPA receptors are ubiquitously 
located throughout the BSC and are the primary means by which glutamatergic 
neurotransmission is mediated (Carlson, 2001b). Accordingly, administration of AMPA 
receptor antagonists or agonists into the BSC impairs or facilitates the expression of 
conditioned fear respectively (Maren, 1999). NMDA receptors, on the other hand, appear to 
play a more global role in fear processing. Their activation is crucial for the consolidation of 
conditioned fear. However, in vitro examination of excitatory neurotramission in the BSC has 
also revealed that NMDA receptors work in conjunction with AMPA receptors during 
excitatory synaptic communication, especially in the spiny projection neurons of the complex 
(Sah, 2003). Thus, NMDA receptors may play a role in the neural dynamics of conditioned 
fear expression. This assumption, however, is the topic of considerable debate (see below). 
Nonetheless, excitatory neurotransmission associated with conditioned fear is predominantly 
mediated by glutamate. 
1.4.3 The Catecholamines  
 
 The catecholamines, dopamine (DA) and noradrenalin (NA), modulate excitatory 
activity in the BSC during processing associated with conditioned fear. The dopaminergic 
and noradrenergic cell bodies are located in the VTA and LC respectively. The arborisations 
from these cells project throughout the brain including a dense projection to the amygdala 
(Chow, 2000). Here these neurotransmitters function as neuronal modulators, since they do 
not directly partake in excitatory neurotransmission. Instead, they notably modulate neuronal 
activity that, in turn, influences cellular excitation (Carlson, 2001b). For example, antagonism 
of D1 and D2 DA receptors in the BSC prevents fear conditioning (for a review see Pezze, 
2004), while inhibiting cellular excitation in the VTA impedes fear expression (Borowski, 
1996; Munro, 1997). In a similar manner, infusing cloidine, the agonist for the α2 NA 
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presynaptic autoreceptor, into the BSC prevents both fear conditioning and expression 
(Davies, 2004; Schulz, 2002). As a result, it has been hypothesized that NA and DA 
significantly facilitate cellular excitation in the BSC, essentially gating information flow 
(Borowski, 1996; McGaugh, 2004; Munro, 1997). Consequently, they act in concert with 
glutamate to induce cellular excitation in the BSC. This increase in excitation is crucial for 
neurotransmission associated with the consolidation and expression of conditioned fear.  
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1.5. Electrophysiology of fear conditioning  
 
Examination of the electrophysiological consequences of fear conditioning has 
revealed that it potentiates CS-evoked excitatory post synaptic potentials (EPSP) in the BSC 
(Collins, 2000; Quirk, 1997; Quirk, 1995). For example, fear conditioning increases the 
magnitude of CS-evoked firing and shortens the latency of firing onset after stimulus 
presentation (Quirk, 1995). This increase in cellular excitation presumably enables the CS to 
induce a fear response via activation of the CE. Research has suggested that this CS 
modification is dependent on the abovementioned convergence of CS- and US-associated 
neurotransmission within the LA (Blair, 2001; Romanski, 1993; Sah, 2003; Schafe, 2005; 
Shi, 1999b, 2001a). Indeed, neurotransmission concerning both stimuli converge on the same 
cells in the LA (Romanski, 1993). Presumably this results in an associative form of synaptic 
potentiation. Whereby, CS associated synapses are potentiated in cells that are receiving CS 
and US associated neurotransmission. Thus, this is thought to be the principal 
neuroanatomical area where the CS fear association is represented. It is noteworthy, however, 
that areas outside of the LA, such as the CE, thalamus, and geniculate nuclei, are also 
implicated in the formation of a fear memory (Apergis-Schoute, 2005; Cahill, 1999; Pare, 
2004; Samson, 2005; Schroeder, 2005). Nonetheless, cellular modifications in the LA appear 
to be especially crucial (Blair, 2005; Maren, 2003; Rodrigues, 2004; Schafe, 2005). Research 
concerning the sub-cellular events within the BSC that could lead to this increase in CS-
evoked activity has revealed that de novo protein synthesis is a key requirement.  
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1.6 Sub-cellular basis of fear memory consolidation   
1.6.1 Fear memory consolidation  
 
Fear memory consolidation is synonymous with long-term memory formation and is 
characterised by de novo protein synthesis in the BSC (Bailey, 1999; Schafe, 2000). 
Presumably these new protein components change the synaptic structure of the cells 
involved, potentiating CS-associated neurotransmission. The synthesis of new cellular 
components requires the activation of a number of protein kinases. Protein kinases act as 
cellular switches; they phosphorylate and functionally change target proteins. These enzymes 
are vital components of signalling cascades that set in motion cellular events required for 
protein synthesis. 
A protein kinase signalling cascade that plays a pivotal role in memory consolidation 
is the extracellular regulated kinase (ERK) signalling cascade. The ERK cascade is a member 
of the mitogen activated protein kinases (MAPK) family of intracellular kinase signalling 
cascades. The primary way in which ERK pathway is activated is by Ras, a small GTPase 
that is localized at the presynaptic and postsynaptic membrane (Kennedy, 2005; Seeger, 
2004). Furthermore, signal transduction pathways initiated by many of the other kinases 
implicated in fear conditioning are known to activate the ERK pathway (Ohtsuka, 1996; 
Selcher, 2002). These include calcium dependent protein kinases (PKC); cyclic-AMP 
dependent protein kinase (PKA); phosphatidylinositol 3-kinsase (PI3-kinase) (Goosens, 
2000; Lin, 2001; Schafe, 2000). Thus, the ERK transduction cascade appears to be a pivotal 
pathway that integrates a number of upstream cellular signals into a cohesive message. 
Activation of the ERK pathway results in gene transcription and subsequent protein 
synthesis. This involves the transcription factor cyclic-adenosine-monophosphate response 
element binding protein (CREB) (Adams, 2000; Sweatt, 2001, 2004). More specifically, 
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CREB promotes the transcription of genes resulting in the production of messenger 
ribonucleic acid (mRNA), which is later transcribed into cellular proteins. Thus, activation of 
the ERK signalling cascade ultimately results in de novo protein synthesis via CREB.  
ERK signalling in both the pre and postsynaptic cell is required for fear memory 
consolidation. Pre-conditioning and intra-LA infusions of the ERK antagonist U0126 
prevents fear memory consolidation while leaving short-term memory, or the acquisition of 
conditioned fear, unaffected. Similar results were obtained when U0126 was infused into 
thalamus, where cell bodies for presynaptic sensory afferents reside (Schafe, 2000, 1999). 
Thus, the ERK signalling transduction pathway plays a pivotal role during fear conditioning 
in both pre and postsynaptic cells. Research concerning the events that lead to ERK 
activation has revealed that calcium influx through the activated NMDA receptor is a key 
prerequisite (English, 1997; Xia, 1996).  
1.6.2 The NMDA receptor 
 
Over the years many researchers have reported that antagonism of the NMDA 
receptor in the BSC impairs fear conditioning (Bauer, 2000; Rodrigues, 2004; Walker, 2000, 
2002). Its characteristic method of activation has provided insight into how it could mediate 
the process. The NMDA receptor is unique as it requires three prerequisites for its activation. 
Firstly, an obligatory glycine and / or d-serine co-agonist must be bound on the extracellular 
side of the receptor. Secondly, the cellular membrane in which the receptor is situated must 
be strongly depolarized. This induces a change in the conformation of the receptor, 
dislodging a magnesium ion that acts as a plug in the receptor channel. Finally, glutamate 
must bind to the receptor free of the magnesium plug. Thus for the receptor to activate during 
synaptic transmission the presynaptic cell must release glutamate while the postsynaptic cell 
is depolarized (Carlson, 2001a). It has been suggested that this occurs during fear 
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conditioning when incoming CS and US neurotransmission converge on the same cells within 
the LA. The US would provide the first prerequisite of receptor activation. Simultaneous 
weak glutamatergic inputs from CS-associated sensory areas would fulfil the second 
requirement (Blair, 2001). This associative input result in NMDA receptor activation, 
specifically at synapses receiving excitatory-CS information (Blair, 2004). Thus, without the 
US, CS-associated excitatory neurotransmission would not activate the receptor. Thus, the 
fact that the NMDA receptor acts as a coincidence detector makes it a valid possibility for 
initiating the cellular events that lead to the CS modifications that underpin fear conditioning. 
However, as mentioned above, in some areas of the BSC, NMDA receptors also appear to 
subserve routine synaptic transmission. However, behavioural examination of unconditioned 
fear has revealed that NMDA receptor activation in the BSC is not required (Van Nobelen, 
2006). Therefore, it is likely that CS-associated neurotransmission in conditioned animals’ 
results in NMDA receptor activation. Whether this actually occurs has been disputed in the 
fear conditioning literature.  
It has been debated whether NMDA receptors in the BSC specifically underpin 
learning, or whether they also play a role in CS associated neurotransmission in fear 
conditioned animals. More specifically, a number of researchers examining the expression of 
conditioned fear have reported that the NMDA receptor is not required (Campeau, 1992; 
Goosens, 2004; Miserendino, 1990). Conversely, others have reported that antagonism of the 
receptor induces a deficit in the retrieval of conditioned fear, indicating that NMDA receptors 
are involved in CS associated neurotransmission in a manner that may account for their 
involvement in the consolidation of learned fear (Fendt, 2001; Lee, 2001; Lindquist, 2004; 
Maren, 1996). One possibility concerning the discrepancy is that NMDA receptors with 
different subcomponents could underlie each process. The NMDA receptor is composed of a 
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principal NR1 subunit and one or more of the modulatory NR2 subunits NR2A-D 
(Stephenson, 2001). NMDA receptors with NR2A and NR2B subunits are highly 
concentrated within the LA (Sah, 2003). The abovementioned researchers, however, have 
used global NMDA receptor antagonists to assess the involvement of NMDA receptors in 
fear conditioning. Selective antagonism of receptors that contain NR2B subunits has revealed 
that these receptors are predominantly involved in fear consolidation (Rodrigues, 2002). 
Receptors that contain the NR2A subunit, on the other hand, are thought largely to play a role 
in neurotransmission (Blair, 2001). Both receptor types are able to bind the scaffold protein 
post synaptic density protein-95 (PSD-95) via their NR2 subunit (Kornau, 1995). The 
partnership between NMDA receptors and this protein serves to assemble multi-protein 
complexes at the postsynaptic membrane necessary for NMDA receptor mediated synaptic 
responses (Wyneken, 2004). Thus, NMDA receptors with NR2A and NR2B subunits are able 
to associate with the same intracellular signalling proteins. One example is the enzyme 
neuronal-nitric oxide synthase (nNOS), which binds directly to PSD-95. Furthermore, nNOS 
is highly concentrated in the LA where, as mentioned, both types of NMDA receptors 
predominate (McDonald, 1993; Unger, 1992). This places the enzyme in an applicable 
position to mediate NMDA associated processes. Neuronal-NOS is activated by calcium that 
passes through the activated receptor via calcium-calmodulin, resulting in the production of 
the small gaseous molecule nitric oxide (NO). Therefore, this gas could be a significant 
intermediary of NMDA receptor activation and fear consolidation and expression. 
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1.7. Nitric oxide 
  
NO is predominantly known as a retrograde neurotransmitter that plays a crucial role 
in the molecular underpinnings of various forms of learning and memory including inhibitory 
avoidance (Calixto, 2001; Meyer, 1998), spatial memory (Holscher, 1996; Zou, 1998), 
habituation (Yamada, 1995), working memory (Cobb, 1995), and olfactory memory (Bohme, 
1993; Dawson, 1994; Samama, 1999). NO is quite a unique signalling molecule for a number 
of reasons: firstly, it is not stored in synaptic vesicles and released via exocytosis, instead it is 
synthesised on demand. Secondly, it is synthesised and released at the postsynaptic 
membrane, rather than at the presynaptic membrane. Thirdly, it can freely diffuse across cell 
membranes. Finally, it has a half life of up to thirty seconds, after which it spontaneously 
decays into nitrate (Lowenstein 1994). In that time, however, it can diffuse in a radius of 
~300 to 350µm and interact with its targets in a non-synaptic manner (Lancaster Jr, 1997; 
Vizi, 2000). Given that the size of a synaptic cleft is approximately 20nm and the size of a 
cell body is a few micrometers (Kiss, 2000), NO has the ability to diffuse across a large 
portion of the cells in the BSC, intercalated masses, and part of the CE, significantly 
modulating activity in its radius.  
The effects of NO can be broadly divided into two types: either soluble guanylate 
cyclase (sGC)-dependent, or sGC-independent (Krumenacker, 2004). In both types of 
signalling NO sets in motion complex signal transduction pathways with numerous 
subdivisions. For example, during sGC dependent process NO binds to sGC, activating the 
enzyme. This results in the synthesis of the second messenger cyclic-guanosine-
monophosphate (cGMP) which, in turn, activates three principal targets: cGMP dependent 
protein kinase (PKG); cyclic-nucleotide gated channels; and cyclic nucleotide 
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phosphodiesterases (Ahen, 2002). Activation of these proteins broadly modifies cellular 
activity; some examples of their actions are mentioned in detail below. NO signalling 
independent of sGC predominantly involves radox reactions. For example, NO can directly 
interact with a target causing its nitrosylation, or NO can interact with an oxygen species 
forming peroxynitrite. Peroxynitrite can subsequently decompose into a number of other 
reactive species, peroxynitrite as well as its products can, in turn, influence cellular activity 
(Ohkuma, 2001). Thus, NO signalling is extremely complex and widespread.  
Overall, NO is an unconventional neurotransmitter and neuronal modulator that acts 
as an extension of NMDA-receptor-mediated glutamatergic activity (Dawson, 1994). It sets 
in motion extensive parallel cellular signal transduction pathways that influence cellular 
activity in a broad manner. Furthermore, because NO is capable of diffusing in such a large 
radius, the synthesis of the gas in the LA could result in NO’s effects reverberating 
throughout a large portion of the amygdala. Consistent with the fact that nNOS could be 
associated with NMDA receptors with either the NR2A or NR2B subunits, many of the sGC-
dependent and independent targets of NO are involved in cellular processes required for 
amygdaloid synaptic transmission or fear memory consolidation.  
1.7.1 Nitric oxide as a modulator of cellular excitation   
 
 As discussed above GABA, glutamate, and the catecholamines all play significant 
roles in modulating neurotransmission in the BSC. Research has indicated that NO can 
modulate the activity of these neurotransmitters. Given that the NMDA receptor is required 
for glutamatergic synaptic transmission in the BSC associated with the recall of conditioned 
fear, NO synthesis may be a significant intermediate step in between NMDA receptor 
activation and excitatory synaptic transmission in the BSC. 
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1.7.1.1 The GABAA receptor  
 
NO is able to significantly reduce GABAergic activity, thus facilitating cellular 
excitation. As discussed above, GABA plays an essential role in inhibiting cellular excitation 
in the BSC via the GABAA receptor, and gates information flow between the BSC and CE 
via the intercalated cells (Lang, 1998; Li, 1996; Royer, 1999; Sanders, 1995; Szinyei, 2000; 
Yamanda, 1999). A number of researchers have reported that NO significantly reduces the 
inhibitory chloride currents that pass through the GABAA receptor in a sGC-dependent 
manner (Robello, 1996; Wall, 2003; Wexler, 1998; Zarri, 1994). For example, Robello and 
colleagues (1996) used whole cell patch clamp recordings to examine GABAA receptor 
functioning in cerebral cells. Bath application of L-arginine, the precursor for NO, 
significantly reduced the chloride current induced by GABA application. This effect was 
diminished by a NOS antagonist and a PKG inhibitor. This indicates that NO mediates its 
effect on the GABAA receptor via activation of this cGMP-dependent kinase (Robello, 1996). 
If NO works in a similar manner in amygdaloid cells it could reduce the inhibitory tone 
imposed by GABA, consequently facilitating excitatory neurotransmission both within the 
BSC and between the BSC and CE. 
1.7.1.2 Glutamate  
 
Research has indicated that NO can increase the extracellular concentration of 
glutamate, thus directly facilitating excitatory neurotransmission (Ohkuma, 2001). For 
example, in vivo microdialysis research in the conscious rat has revealed that the NO donor 3-
morpholino-sydnonimine (SIN-1) increases the extracellular concentration of glutamate in 
the hippocampus and striatum up to 197% above baseline levels (Segovia, 1994). It appears 
that NO can induce this release by directly interacting with vesicle docking proteins at the 
presynaptic cell membrane, consequently facilitating glutamate liberation into the synaptic 
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cleft (Meffert, 1996, 1994). If NO acts this way in the LA it could directly facilitate 
excitatory neurotransmission by increasing the extracellular concentration of glutamate.  
 1.7.1.3 The Catecholamines  
 
NO can also modulate excitatory neurotransmission by increasing extracellular 
catecholamine concentrations (Guevara-Guzman, 1994; Kiss, 2000; Prast, 2001). NO does 
this by functionally altering the catecholamine reuptake systems. Firstly, NO is able to inhibit 
their reuptake transporters, preventing the catecholamines that are liberated during 
neurotransmission from being taken back up into the presynaptic cell (Kiss, 2001, 2004). For 
both the catecholamines, NO modulates the reuptake systems in a sGC-independent manner. 
More specifically, NO directly interacts with the NA transporter preventing it from 
functioning; conversely it inhibits the DA transporter via peroxynitrite (Fleckenstein, 1997; 
Kaye, 2000). Additionally, Lonart and colleges have reported that NO can reverse each 
transporter, consequently increasing the extracellular concentration of both neurotransmitters 
(Lonart, 1993, 1992). Thus, NO is able to enhance the extracellular concentration of both DA 
and NA by altering their reuptake systems. Because the catecholamines significantly facilitate 
cellular excitation in the BSC NOs ability to modulate their activity could have considerable 
effects on neurotransmission associated with conditioned fear.  
1.7.1.4 Summary  
 
NO could, therefore, significantly increase the excitatory tone of the BSC, and thus 
play an important role during the expression of learned fear. More specifically, CS associated 
neurotransmission in the amygdala could activate NMDA receptors, especially those 
containing the NR2A subunit, resulting in the synthesis of NO. NO would diffuse in a 
spherical manner increasing cellular excitation in its radius. Thus, NMDA receptor activation 
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could influence the activity of many cells in the vicinity, thus having a more global effect on 
the BSC structures rather than only affecting the cell in which the NMDA receptor resides. 
However, a general increase in cellular excitation could also facilitate the initial consolidation 
of learned fear. Thus, NO acting in the above mentioned manner could influence both fear 
memory recall and its consolidation. However, NO can also modulate some of the cellular 
machinery specifically required for long-term fear memory formation. 
1.7.2 Nitric oxide in memory consolidation 
 
 As discussed above de novo protein synthesis is a fundamental requirement of fear 
memory consolidation. Moreover, the NMDA receptor has been implicated in this activity. 
As discussed next, NO can directly modulate the cellular machinery required for protein 
synthesis. Thus, it could be the intermediate step between NMDA receptor activation and fear 
memory consolidation.  
1.7.2.1 Extracellular regulated kinase  
 
NO can link NMDA receptor activation with ERK signalling. NO is able to activate 
Ras, a signalling protein that is required for fear conditioning (Brambilla, 1997, Merino, 
2006) and is a principle activator of the ERK signalling pathway (Lander, 1996, 1995; Yun, 
1999, 1998). NO activates Ras by directly interacting with the protein (Lander, 1995;. Yun, 
1998). Given that ERK signalling in both the pre and postsynaptic cell is required for fear 
memory consolidation and that Ras is located at both the presynaptic and postsynaptic 
membrane (see above), it seems plausible that NO could activate this signalling pathway in 
both cells. Thus, NO may link NMDA receptor activation with ERK signalling. However, 
NO’s possible contribution to protein synthesis does not end there. As mentioned, ERK 
signalling leads to gene transcription via CREB; NO can also activate CREB.  
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1.7.2.2 CREB  
 
 NO can promote the activation of CREB, consequently playing a more direct role in 
protein synthesis by facilitating the transcription of mRNA. NO can activate CREB in a sGC-
dependent manner. Specifically, researchers examining late phase long-term potentiation (L-
LTP) in hippocampal cells, an in vitro phenomenon that is analogous to memory 
consolidation (Blair, 2001; Dityatev, 2005; Laroche, 2000; Maren, 2005; Silva, 2003), 
reported that inhibiting PKG activity blocked L-LTP (Lu, 1999). Examination of how PKG 
mediates its effects revealed that inhibiting the kinase reduced CREB phosphorylation (Lu, 
1999). Thus, the NO-sGC-cGMP-PKG pathway contributes to CREB phosphorylation in the 
hippocampus. As a result, this pathway can modulate the transcription of genes from the cell 
nucleus. NO could also play a similar role in the BSC during fear memory consolidation, 
thereby contributing to NMDA-receptor-mediated protein synthesis.  
1.7.2.3 Summary  
 
 Overall, NO is able to modulate ERK and CREB signalling, contributing to protein 
synthesis in both a sGC-independent and sGC-dependent manner respectively. Thus, NO 
could link NMDA receptor activation, specifically those that contain the NR2B subunit, with 
cellular events required for the long-term cellular modifications that underpin fear memory 
consolidation. Indeed, this seems feasible when considering that fear memory consolidation 
requires the post and pre synaptic cell, indicating that a retrograde messenger may be 
involved.  
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1.8 Reasons for this current study 
 
NO is an extremely promiscuous molecule, it essentially acts as an extension of 
glutamatergic synaptic transmission via activation of the NMDA receptor. The fact that NO 
can modulate neurotransmission as well as cellular processes required for fear memory 
consolidation is fitting when considering that NMDA receptors, especially those with NR2A 
and NR2B subunits respectively, have been implicated in both processes. Thus, NO synthesis 
could significantly subserve NMDA receptor activation and both processes. It must be 
mentioned, however, that the above overview of NO’s actions is in no way exhaustive and 
predominantly mentions research where brain areas outside of the amygdala were examined. 
Nonetheless, there is no reason to believe that NO would not act in a similar manner in the 
BSC.  
The first step in this research area is to determine whether NO plays a significant role 
in the BSC during processing associated with conditioned fear. Recently there has been an 
increase in research concerning this very endeavour. For example, examination of LTP in 
amygdaloid cells has revealed that an increase in NO activity significantly augments the 
process (Chien, 2003). This indicates that NO could play a role in amygdaloid mediated 
memory formation. Moreover, infusion of the NO donor SIN-1 into the amygdala results in 
activation of the hypothalamic-pituitary-adrenal axis, a process that is known to occur during 
the initiation of a fear response (Herman, 2004; Seo, 2001), thereby, showing that NO 
activity pays a role in fear associated amygdaloid functioning. Direct examination of NO’s 
role in fear conditioning, however, has revealed that it is exclusively required for fear 
memory consolidation. More specifically, Schafe and colleagues (2005) reported that intra-
LA microinfusions of the selective nNOS inhibitor 7-nitroindazole (7-Ni) did not effect short-
term memory formation, fear expression, and the re-consolidation of learned fear. However, 
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the CS used in this series of experiments was auditory and fear learning was assessed by 
examining CS induced defensive freezing. Thus, it is important to ascertain whether these 
findings can extend to fear conditioning when the CS is visual and FPS is used to examine 
fear expression.  
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1.9 Experimental procedures employed in this study 
1.9.1 Fear potentiated startle 
 
 A FPS paradigm was employed in the current study to determine whether rats can 
learn a CS-US fear association, and express conditioned fear when NO synthesis is inhibited 
in the BSC during each process. During the conditioning procedure the animals were 
conditioned to fear a light. During the subsequent testing session, baseline acoustic startle 
reflex amplitudes of the fear conditioned animals were obtained and compared with those 
acquired when the acoustic stimulus and the CS were presented simultaneously. Because of 
the arousing characteristic of fear if the animals had learnt the fear association their acoustic 
startle responses were potentiated in the presence of the CS. One of the strengths of the FPS 
paradigm is that it is not species typical and can be reliably observed in humans by using the 
eye-blink component of FPS. Researchers using this method have reported that FPS in 
humans shares many characteristics to those observed in animal populations. For example, 
FPS is enhanced when human subjects are exposed to a CS previously paired with a US 
(Grillon, 1997; Jovanovis, 2005), when they anticipate shock (Grillon, 1995; Morgan, 1995), 
and when they have been exposed to an aversive stimulus (Bradley, 2001). Furthermore, FPS 
in humans also requires an intact temporal lobe (Buchanan, 2004). Thus, because of these 
similarities the FPS paradigm has a great deal of face validity in experimental analyses of the 
neural systems and molecular events involved in fear and anxiety. Thus, FPS was employed 
in the current study to assess whether rats learnt a CS-US fear association, and whether they 
could express conditioned fear.  
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1.9.2 Shock sensitization of the acoustic startle  
 
 The shock sensitization of the acoustic startle paradigm was used to determine 
whether animals can express fear when NO signalling is inhibited in the BSC. The shock 
sensitization effect is characterised by an enhancement of acoustic startle amplitudes 
immediately following several un-signalled shock presentations. It has been suggested that 
this is a manifestation of an unconditioned fear response (Davis, 1989). An alternative view is 
that it is an expression of conditioned fear. More specifically, it has been suggested that the 
shock increased acoustic startle results from rapid conditioning to the context in which the 
shock was delivered (Richardson, 1999; 1998). Research from our laboratory supports the 
prior hypothesis. For example, infusion of the global NMDA receptor agonist D(-)-2-Amino-
5-phosphonopentanoic acid (AP-5), into the BSC did not influence the shock sensitization 
effect (Van Nobelen, 2006). Contextual conditioning, on the other hand, does require NMDA 
receptor activation (Maren, 1996), thus suggesting that shock increased acoustic startle is 
indeed an expression of unconditioned fear. Thus, a shock sensitization paradigm was used in 
this current study to examine unconditioned fear.  
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1.10 The aims and hypotheses of the current study 
 
 The first aim of this study was to determine whether NO signalling in the BSC is 
required for fear memory consolidation. To ascertain whether this is indeed the case, the 
effect of two doses of the global NOS inhibitor N-nitro-l-arginine methyl ester (L-NAME) on 
the consolidation of conditioned fear were examined. No previous study has examined 
whether NO is required for fear conditioning when the CS is visual and FPS is used to 
examine fear responding. This is surprising for a number of reasons: firstly, the enzyme 
responsible of NO synthesis, nNOS, is highly concentrated in the LA, which is the 
neuroanatomical location of the amygdala where the crucial component of CS-US engram is 
thought to reside. Secondly, with this paradigm NMDA receptor activation is the prerequisite 
for memory consolidation. Thirdly, NO is able to modulate cellular processes that underpin 
fear memory consolidation. Fourthly, research is emerging that suggests NO signalling plays 
a role in amygdaloidal functioning. Finally, research over the last decade has revealed that 
NO signalling plays a crucial role in the formation of many forms of memory. Therefore, it 
was hypothesised that inhibiting NO signalling in the BSC will prevent fear memory 
consolidation. 
 The second aim of the current study was to determine whether NO is required for the 
expression of learned fear. No previous study has examined whether NO could be involved in 
the expression of visual conditioned fear using a FPS paradigm. Again this is unexpected 
when considering that NMDA receptor activation is required for the expression of fear using 
this testing procedure and that NO is able to modulate processes required for 
neurotransmission in the amygdala. Therefore, it was hypothesised that inhibiting NO 
synthesis would prevent the expression of learned fear.  
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 The third aim of this study was to determine whether NO signalling in the BSC is 
required for the enhanced acoustic startle observed in the shock sensitization of the acoustic 
startle paradigm. Once again, no previous researchers have examined whether NO could play 
such a role. Because the NMDA receptor is not required for this effect it was hypothesised 
that NO signalling in the amygdala is not required for this effect (Van Nobelen, 2006). 
Nonetheless, it was important to determine whether the animals can experience and express 
unconditioned fear so that the results from the fear consolidation and fear expression 
experiments can be attributed specifically to memory deficits rather than deficits in emotional 
responding.  
The final aim of this study was to eliminate two other possible confounds. 
Specifically, whether inhibiting NO synthesis modifies normal baseline acoustic startle 
responding or the perception of footshock. The first of which could effect the interpretations 
drawn from the results of the fear expression experiment. The second could effect how one 
interprets the fear conditioning experiment. It was hypothesised that inhibiting NO synthesis 
would not modify these behaviours.  
Overall, it was hypothesised that intra-BSC NO signalling is a significant extension of 
NMDA receptor activation associated with the consolidation of learned fear and its 
subsequent expression. Inhibiting NO’s synthesis in the BSC should accordingly interfere 
with both processes. It was, conversely, anticipated that NO is not required for the expression 
of unconditioned fear, baseline acoustic startle responding, or the perception of footshock. 
Therefore, inhibiting the synthesis of NO in the BSC should not modify shock enhanced 
acoustic startle responding, or alter these routine behaviours. 
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2. Method 
2.1 Subjects  
 
 Fifty male albino rats of the Wistar strain bred in the Psychology Department at the 
University of Canterbury served as subjects. They were group-housed 4 per cage in a colony 
room maintained at 22ºC and 48% rH. The colony was kept on a 12-h light dark cycle, lights 
on at 8.00 A.M, behavioural testing was conducted in the light portion of the cycle. At the 
beginning of the experiment the animals were approximately 3 months of age and weighed 
between 300 and 350 g. Throughout the study the animals had free access to food and water. 
All experimental procedures conformed to national and international guidelines for the 
ethical use of laboratory animals and followed protocols approved by the University of 
Canterbury Animal Ethics Committee.  
 
2.2 Apparatus  
  The acoustic startle reflex amplitudes of the animals were measured in four identical 
startle cages (16.5 X 8.0 X 9.0 cm) (Med Associates, Fairfield, VT), located in sound 
attenuating melamine chambers (60 X 34 X 56 cm). A 2.8-W lamp and a 6.0-cm speaker 
were positioned 10 cm from each startle cage. The lid and walls of each cage consisted of 
horizontal stainless steel rods 0.25 cm in diameter and spaced 1.5 cm apart. The chamber 
floors were also comprised of stainless steel rods 0.45 cm in diameter and spaced 1.10 cm 
apart. The cages were located on top of a startle platform (25 x 11.5 x 4.5 cm) that contained 
a load-based cell that measured startle amplitudes. The analogue amplitudes were filtered to 
control for electrical noise through a Med associates startle transducer, amplified, and 
converted to a digital signal (0.5 V peak voltage amplitude equals 100 units). Med associates 
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startle reflex software version 5.6 recorded the startle amplitudes, and controlled the 
presentation of light, shock, and white noise stimuli. The acoustic stimulus was produced by 
a programmable audio generator and was a 100 ms white noise burst with a rise and fall time 
of 5 ms. The ambient noise level in the chambers was 36 dB, measured with a Bruel and 
Kjaer (Model 2235; Denmark) sound level meter (A-scale). The 600-µA footshock was 
presented through the grid floor of the startle chambers by a constant current scrambled shock 
generator.  
2.3 Drug: 
 
The global NOS inhibiter N(G)-nitro-l-arginine methyl ester (L-NAME), was 
purchased from Sigma-Aldrich (Auckland, New Zealand), dissolved in physiological saline 
(pH = 7.4) and infused in a volume of 0.5 µl per side. The dosages used (1.0 and 0.1 µg) were 
within the range used by previous researchers who have infused L-NAME into the central 
nucleus of the amygdala, and the dorsal raphe nucleus before conducting behavioural tests 
(Grahn, 2000; Zarrindast, 2002). The most effective dose ascertained from the fear 
consolidation experiment was subsequently used in both the fear expression and shock 
sensitization experiments.  
2.4 Surgical procedures  
 
 Stereotaxic surgery was preformed under aseptic conditions. Thirty min before 
anaesthetic was administered each animal received an intraperitoneal (IP) injection of 
atropine (0.2 mg/kg) in order to prevent mucus build-up in the respiratory system and to 
facilitate respiration. They were subsequently anesthetized with an IP injection of sodium 
pentobarbitone (92 mg/kg). After the induction of anaesthesia 0.2 ml of the local anaesthetic 
mepivicane was subcutaneously administered at the top of the animal’s skull at the 
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approximate location where an incision would be subsequently made. This was followed by 
subcutaneous administration of 0.2 mg/kg of the analgesic ketophen between the neck and 
shoulders. Four min later the animals were mounted in a stereotaxic instrument (Wood Dale, 
IL, USA). The incisor bar was adjusted so that the horizontal plane was level at Lambda and 
Bregma. An incision was then made to expose the bone at the top of the animal’s skull. All 
rats received bilateral 22-gauge (0.71 mm) guide cannula (C313G; Plastics One, Roanoke, 
VA) implants aimed 1.0 mm above the lateral portion of the BSC in both hemispheres (AP: -
2.8mm posterior from bregma; ML: ±4.8mm from the sagittal suture; DV: - 8.2mm from the 
skull surface). Both implants were perpendicular to the horizontal plane. Coordinates were 
obtained from the Paxinos and Watson (1997) stereotaxic brain atlas for the rat. The cannulae 
were fixed to the skull with stainless steel screws and dental cement, and 28-guage (0.36 mm) 
dummy stylets (C313DC, Plastic one) were placed within the shaft of each cannula to prevent 
blockage. 
2.5 Base line assessment of acoustic startle amplitudes 
 
 For each animal, the dB noise level required to produce average acoustic startle 
amplitudes approximating 200 units was determined 5 to 7 days after surgery. Rats were 
placed in the startle chambers and allowed 4 min to adapt to the environment. Next they were 
presented with 60 noise bursts (95db). The following day, the noise level for each animal was 
adjusted so that acoustic startle amplitudes would approximate the desired level (generally an 
increase or decrease of 3 dB was required). The acoustic startle of each subject was then 
reassessed using the same procedures as the previous day. For each animal, the dB noise level 
that provoked average startle amplitudes approximating 200 units was used for all subsequent 
experiments; noise levels for all animals were between (87-98 dB).  
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2.6 Microinfusion process 
 
During the infusion process the animals were hand held, and the dummy stylets 
removed. Two 28-guage (0.36 mm) infusion needles (C3131, Plastic One) preloaded with the 
appropriate drug concentration were inserted into each guide cannulae. Both extended 1.0 
mm below the tip of the guide cannula and were attached to drug-filled polyethylene tubes 
(PE20, Plastics One) connected to 2.0 µl Hamilton syringes (Hamilton Co., Reno, NEV). The 
syringes were located in a Stoelting infusion pump (model 310; Stoelting Co., Wood Dale, 
IL). The bilateral infusions were made over 1 min, and the infusion needles were kept in 
place for a further 2 min to allow the drug to diffuse from the tip. Following the removal of 
the needles the dummy stylets were promptly reinserted.  
2.7 The Fear conditioning experiment   
  
Twenty-four hours after baseline assessment 21 rats were randomly assigned to 3 
groups (N = 7), and received intra-BSC microinfusions of either saline or one of two doses of 
L-NAME (1.0 or 0.1µg) using the methods outlined in section 2.6.  
2.7.1 The fear conditioning procedure 
 
Immediately after drug infusion the rats were placed in the startle chambers and 
allowed 10 min to adapt to the apparatus and for the drug to diffuse throughout the target 
area. This time frame is consistent with that used by Grahn et al. (2000) who waited 10 min 
before behavioural testing after micro-infusing L-NAME into the dorsal raphe nucleus. The 
rats were then presented with 10 light + footshock pairings, at an inter-stimulus-interval (ISI) 
of 2 min. The light was presented for 3500 ms, and co-terminated with a 250-ms footshock.  
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2.7.2 Assessment of fear potentiated startle  
 
For each rat, fear potentiation of acoustic startle was assessed 24 h after conditioning. 
The rats were placed in the startle chambers and allowed 4 min to adapt. Firstly, they were 
exposed to a block of 30 noise bursts. This first block was presented so that the animals 
would habituate to the stimuli, as animals exhibit abnormally high startle responses occur 
over the first few noise presentations. Consequently, startle responses from this block were 
not included in the subsequent analysis. Next, the animals were presented with a block of 5 
noise-alone trials, followed by a block of 5 light + noise presentations. The light was 
presented for 3.5 s and co-terminated with a 100-ms noise burst. Across all blocks the ISI was 
30 s (see Figure 1). 
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Figure 1 Schematic of the procedure used to determine whether intra-BSC microinfusions of L-
NAME (1.0 and 0.1µg) prevented fear memory consolidation. Animals were tested at 
approximately the same time each day. Darkened box denotes that the procedure occurred 
immediately after drug infusion.  
 
2.7.3 Data analysis 
 
 For each rat, acoustic startle amplitudes were average within the second block of five 
noise-alone trials and the third block of five light + noise trials. The average acoustic startle 
amplitude from the light + noise trails was subtracted from the average acoustic startle score 
from the noise-alone trails to give an average difference score. Results were analysed using a 
2 (Block) X3 (Group) repeated-measures ANOVA design with the block factor as the 
repeated measure. Simple effects analyses were conducted to examine differences in group 
means. Furthermore, mean difference scores from the three groups were compared with each 
Baseline assessment 
30 noise bursts 
 
 
Conditioning  
      10 light + footshock pairings  
Baseline assessment 
30 noise bursts 
Assessment of fear potentiated 
startle  
   30 baseline noise presentations 5 noise 
bursts - 5 light plus noise trials  
Day 2  
Day 4  
Day 3  
Day 1  
  
37 
other using a one-way ANOVA. Simple effects analyses were conducted to determine which 
means differed from each other.   
2.8 The expression of learned fear experiment  
 
Twenty-four hours after baseline assessment (see 2.5) 13 animals were fear 
conditioned using the same methods as described above (see 2.7.1). However, the animals 
received 20 light + shock pairings, and the shock duration was 500 ms. Approximately 24 h 
later the animals were randomly assigned to two groups and received bilateral microinfusions 
of either saline (N = 7) or 0.10 µg of L-NAME (N = 6) see section 2.6. After infusion the rats 
were promptly placed in the startle chambers and allowed 4 min to adapt. Next, they were 
presented with 10 noise bursts. Consistent with above, this first block of noise bursts was 
presented in order to allow the animals to habituate to the presentation of stimuli, and results 
were not included in the subsequent analysis. The number of noise presentations in this first 
block was substantially less than the FPS assessment in the previous fear conditioning 
experiment, as it had been determined from the findings of the previous study that the drug is 
effective 10 min after infusion. Thus, the procedure for this experiment was adjusted so that 
the animals were presented with the final two blocks approximately 10 min after infusion. 
Next the animals were presented with a second block of 5 noise-alone trails, and a final block 
of 5 noise + light trials. As with the previous experiment, the light was presented for 3.5 s and 
co-terminated with a 100-ms noise burst. The ISI across all blocks was 30 s (see Figure 2).  
 
 
 
 
 
  
38 
Day 1  
Day 3  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
  
 
 
 
 
 
 
Figure 2. Schematic of the procedure used to determine whether 0.1µg L-NAME microinfused 
into the BSC significantly attenuated the expression of conditioned fear. Animals were tested at 
approximately the same time each day. Darken box denotes that the procedure occurred 
immediately post infusion.  
 
 
2.8.1 Data analysis 
 
Group means were calculated in the same manner as the fear conditioning experiment 
(2.7.3). Data was analysed using a 2 (Block) X2 (Group) repeated measures ANOVA design 
with the block factor as the repeated measure. Simple effects analyses and a t-test were 
conducted to determine whether differences between group means were significant.  
2.9. The shock sensitization experiment  
 
 Twenty-four hours after baseline assessment (see 2.4) 16 animals were randomly 
divided into two groups: a saline-control group (N = 8) and an L-NAME group (N = 8). The 
Baseline Assessment 
30 noise bursts 
Baseline Assessment 
30 noise bursts 
Assessment of fear potentiated startle:  
    10 baseline noise burst, 5 noise bursts, and 
5 light + noise burst  
 
 Conditioning  
      20 light + foot-shock pairings  
Day 2  
Day 4  
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Day 3  
rats were placed in the startle chambers and allowed 4 min to adapt. They were then 
presented with a pre-infusion block of 20 noise bursts. The animals were promptly removed 
from the chambers and received bilateral microinfusions of either 0.1 µg of L-NAME, or 
saline (see 2.6). Immediately following infusion the animals were returned to their original 
startle chambers, and allowed 1 min to re-adapt. The rats were then presented with a second 
post-infusion / pre-shock block of 20 noise bursts. Followed by 10 500-ms foot shocks at an 
ISI of 10 s, finally they were presented with a post-shock block of 20 noise bursts. All noise 
burst were presented at an ISI of 30 s (see Figure 3).  
 
 
 
    
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic of the procedure used to determine whether 0.1 µg of L-NAME 
microinfused into the BSC significantly affected baseline acoustic startle amplitudes, shock 
reactivity, or shock sensitization of the acoustic startle. Animals were tested at approximately 
the same time each day. Darken box indicates that the procedure occurred immediately after 
drug infusion.  
 
Pre-infusion baseline 
20 noise bursts  
 Assessment of shock sensitization: 
    20 post- infusion noise bursts, 10 footshocks, 
20 post-shock noise bursts 
Baseline Assessment 
30 noise bursts 
Day 2  
Day 1  
Baseline Assessment 
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2.9.1 Data analysis  
2.9.1.1 Effect of L-NAME on baseline acoustic startle reactivity  
 
 For each rat, the average acoustic startle scores in the pre-drug infusion block and the 
post-drug infusion block were determined. The average from the post-drug infusion block 
was subtracted from the average from the pre-infusion block to give an average difference in 
drug induced acoustic startle responding. Results were analysed in the same manner as 
described in section 2.8.1. 
2.9.1.2 Effect of L-NAME on shock reactivity  
 
 For each rat, the average movement amplitudes 250-ms pre-shock onset and 250-ms 
post-shock onset were calculated. Average movement amplitudes from the post-shock were 
subtracted from average movement amplitudes pre-shock to give an average increase in 
movement amplitude induced by footshock. Inferential analyses were conduct in the same 
manner as described in section 2.8.1. 
2.9.1.3 Effect of L-NAME of shock sensitization of acoustic startle  
 
 For each rat, average acoustic startle responses in the post-shock block were 
calculated. The average acoustic startle scores from the post-drug block (see 2.7.1.1) were 
subtracted from the average startle in the post-shock block to give an average difference score 
indicative of shock enhanced arousal. Again, inferential analyses were conducted in the same 
manner as described in section 2.8.1. 
2.10. Histology  
 
 The rats were euthanazed with an overdose of sodium pentobarbitone and perfused 
intracardially, first with 200 ml of saline followed by 200 ml of 10% formaldehyde. The 
brains were promptly removed and stored in ten percent formaldehyde for approximately 2 
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days, and then transferred to a long-term 70% sucrose solution for a minimum of a week. 
Coronal sections of 50 µm were cut using a cryostat, mounted on gelatine coated slides, and 
stained with Cresyl Violet. Cannulae placements were subsequently verified using a light 
microscope. The placements were confirmed and reconstructed on representative coronal 
sections taken from the Paxinos and Watson rat brain stereotaxic atlas (Paxinos, 1997). Data 
from animals with placements that indicated that the infusion stylets were not within 0.5 mm 
of the basolateral complex, or where the guide cannulae had damaged the amygdala, were not 
included in the subsequent analysis.  
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3. Results 
3.1 Histology:  
 
 Figure 4 depicts the intra-BSC injections sites of L-NAME for groups from the fear 
conditioning, fear expression, and shock sensitization of the acoustic startle experiments. All 
placements are superimposed on coronal sections taken from Paxinos and Watson (1997). As 
illustrated, injection sites were predominantly in the medial-lateral portion of the BSC.  
 
Figure 4. Schematic coronal sections through the rat brain showing the intra-BSC injection sites of L-NAME. The 
1.0 and 0.1 µg fear conditioning groups are depicted in a i and ii respectively. The 0.1 µg fear expression group is 
depicted in b. The 0.1 µg shock sensitization group is shown in c. Arrows indicate the site of the BSC. Schematics 
are adapted from Paxinos and Watson (1997). Numbers are distances from Bregma 
a i a ii 
b c 
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3.2 Fear conditioning experiment  
 
 The aim of the fear conditioning experiment was to determine whether NO plays a 
significant role in the molecular underpinnings of fear memory consolidation. It was also 
necessary to establish at what concentration L-NAME is most effective at inhibiting this 
phenomenon, in order to determine the most desirable drug concentration that could be used 
for the subsequent experiments. During the conditioning procedure the animals were required 
to learn that the presentation of a light-CS predicts the occurrence of a footshock-US. The 
consolidation of this association was assessed using a FPS paradigm with the dependent 
measure being the animal’s acoustic startle response during the noise-alone trials and the 
noise + light trials. For each rat, average acoustic startle responses in the noise + light trials 
were subtracted from the average acoustic startle responses from the noise-alone trials to 
produce an average difference score (Appendix A). Thus, high difference scores were 
indicative of fear induced potentiation of the acoustic startle and thus fear memory 
consolidation.  
Figure 5 shows the average noise-alone and noise + light startle amplitudes, along 
with and the average difference between these two blocks for the three groups. The figure 
shows that the acoustic startle levels for each group were equivalent in the noise-alone block. 
However, in the noise + light block the acoustic startle responses of the saline group 
increased substantially compared with the two drug groups. Thus, the difference score for the 
control group was substantially larger than those for two drug groups. 
A 2(Block: noise-alone and noise + light) X3 (Group: saline, 1.0, and 0.1µg of L-
NAME) repeated-measures ANOVA with Blocks as the repeated factor yielded a significant 
effect of Blocks, F(1,18)=9.51,p<0.007, and a significant Group X Block interaction, 
F(2,18)=3.90,p<0.04, without a Group main effect (Appendix B). Simple effect analyses 
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confirmed that the acoustic startle amplitudes of the control group increased significantly on 
the noise + light as compared with the noise-alone, F=16.45,p<0.0008. Conversely, the two 
drug groups exhibited similar startle amplitudes on the baseline and CS + Noise stimulus 
blocks, 1.0µg F=0.57,p>0.4; and 0.1µg F=0.28,p>0.6. The difference scores for the three 
experimental groups differed significantly when compared with each other: 
F(2,18)=3.90,p<.04 (Appendix C). Simple effects analysis revealed that the difference score 
of the control group was significantly larger than those of the two drug groups, 1.0µg, 
F=5.46,p<0.04; 0.1µg, F=6.21,p<0.03, while the two drug groups did not differ significantly 
from each another, F=0.024, p>0.8. Thus, both dosages of L-NAME impaired the capacity of 
animals to condition to a light CS.  
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Figure 5. Average acoustic startle scores (+SEM) for groups that received intra-BSC 
microinfusions of L-NAME (1.0, 0.1µg) or saline per side prior to conditioning 24 hours 
previously. N=7 in each group. * p < 0.05 relative to noise-alone trials, ** p < 0.05 relative to 
saline group. 
 
 
 
 
   * 
    **     ** 
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3.3 Fear expression experiment: 
 
The aim of the fear expression experiment was to determine whether NO is required 
for the expression of conditioned fear. Specifically, it was conducted to determine whether 
the lowest dose of L-NAME the significantly impaired memory consolidation would also 
prevent fear memory recall. As with the previous experiment, the animals were required to 
learn that the CS predicts the US, and a FPS paradigm was used to assess whether the animals 
had indeed learnt this association. Accordingly, the dependent measures were the animal’s 
acoustic startle response during the noise-alone trails and the noise + light trials. For each 
animal, average acoustic startle responses in the noise + light trials were subtracted from the 
average acoustic startle responses from the noise-alone trials to produce an average difference 
score (Appendix D). Thus, high difference scores were indicative of fear potentiation of 
acoustic startle and thus the expression of learned fear.  
 Figure 6 shows the average acoustic startle response during the noise-alone trials, the 
noise + light trails, and the average difference between these blocks for both the saline-
control and L-NAME groups. The figure illustrates that all groups exhibited similar acoustic 
startle amplitudes in the noise-alone trails. In the noise + light block the acoustic startle 
amplitude of the saline-control group increase substantially compared with that of the L-
NAME group. Thus, the control group appeared to have a significantly large difference score.  
A 2(Blocks: noise-alone and noise + light) X2 (Group: saline and L-NAME) 
repeated-measures ANOVA with the Blocks factor as the repeated measure yielded a 
significant main effect of Blocks, F(1,11)=5.73,p<0.04, and a significant Block x Group 
interaction F(1,11)=4.87,p<0.05, in the absence of a Group main effect (Appendix E). A 
simple effects analysis confirmed that the startle responses of the control group were 
significantly higher on the noise + light presentations compared with the noise-alone trials, 
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F=11.47, p<0.007, while the acoustic startle amplitudes of the L-NAME group did not differ 
significantly across these two stimulus blocks, F=0.02,p>0.9. Further comparison of the 
difference scores using a t-test for dependent means revealed that the score for the control 
group was significantly larger than that of the L-NAME group t(11)=2.21,p<0.05. Thus, L-
NAME microinfusions into the BSC impaired the capacity of animals to recall a light-CS fear 
association.  
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Figure 6. Mean acoustic startle amplitudes (+SEM) after intra-BSC bilateral microinfusions 
of saline or 0.1µg of L-NAME prior to fear testing. L-NAME group (N = 7), Saline group (N 
= 6). Animals were fear conditioned 24 hours previously. * p < 0.05 relative to the noise-
alone trails, ** p < 0.05 relative to the saline group. 
       * 
         ** 
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3.4 Shock sensitization experiment:  
 
 The first aim of the shock-sensitization experiment was to assess whether NO is 
required for the shock sensitization of the acoustic startle effect. That is, this experiment was 
conducted to ascertain whether the animals can express fear when L-NAME is infused into 
the BSC, thus ensuring that the results from the fear expression experiment can be attributed 
to a deficit in memory retrieval rather than emotional responding. Furthermore, it would 
ensure that the results of the fear conditioning experiment can be attributed to a deficit in fear 
learning rather than the animals not perceiving fear in the presence of the US. More over the 
procedure employed in this experiment served to address to possible confounds, specifically 
whether (1) L-NAME microinfused into the BSC modified the animal’s baseline acoustic 
startle responding; or (2) perception of footshock.  
3.4.1 Effect of L-NAME infusion on baseline acoustic startle reactivity 
 
 The dependent measure in this experiment was the animals’ acoustic startle responses 
during the pre-drug infusion and post-drug infusion blocks of noise bursts. For each animal, 
the average acoustic startle responses in the pre-drug infusion block were subtracted from the 
average acoustic startles from the post-drug infusion block to give a difference score 
(Appendix F). If L-NAME did affect baseline acoustic startle amplitudes then amplitudes in 
the pre-infusion block would have been substantially different from those observed in the 
post-infusion block, resulting in either a significantly large or small difference score. 
  Figure 7 shows the average pre-infusion and post-infusion acoustic startle scores and 
the average difference between these two blocks for both the control and L-NAME groups. It 
illustrates that the pre-infusion and post-infusion scores for the L-NAME group were 
equivalent, resulting in small difference score. On the other hand, the acoustic startle 
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responses of the control group increased somewhat in the post-infusion block compared with 
the pre-infusion block, resulting in a moderate difference score.  
However, a 2(Blocks: pre-infusion and post-infusion) X2 (Group: saline and L-
NAME) repeated-measures ANOVA with the Blocks factor as the repeated measure revealed 
no significant main effects or interaction effects (Appendix G). Thus, simple effect analysis 
indicated that the difference between the pre-infusion and post-infusion blocks was not 
significant for either the control, F=2.46,p>0.1, or L-NAME, F=0.03,p>0.8 group. Also, a t-
test for independent means revealed that the control and L-NAME groups differences scores 
were equivalent, t(14)=0.98,p>0.3. Thus, we can conclude that the L-NAME infusions into 
the amygdala does not alter baseline startle responding.  
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Figure 7. Mean acoustic startle amplitudes (+SEM) as a function of intra-BSC 
microinfusions of saline (N = 8) or 0.1µg of L-NAME (N = 8) into the BSC.  
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3.4.2 Effect of L-NAME infusion on shock reactivity  
 
The dependent measure in this experiment was the animals’ average movement 
amplitudes 250-ms pre-shock onset and 250-ms post-shock onset. Average movement 
amplitudes post-shock onset were subtracted from the average movement amplitudes pre-
shock onset to give an average difference in movement reactivity that was indicative of shock 
perception (Appendix H). Thus, if the animals perceived footshock in a normal manner then 
the difference score were substantially large.  
 Figure 8 shows the average movement amplitudes 250-ms pre-shock onset and 250-
ms post-shock onset for both the L-NAME and saline groups. The figure shows that both 
groups exhibited a substantial and equivalent increase in acoustic startle amplitude in the 
250-ms post-shock block compared with the 250-ms pre-shock block, resulting in equally 
large difference scores.  
A 2 (Shocks: 250-ms pre-onset and 250-ms post-onset) X2 (Group: saline and L-
NAME) repeated-measures ANOVA with Shocks as the repeated factor did, indeed, yield a 
highly significant main effect of Shocks F(1,14)= 394.70,p<0.000000, without any other 
significant effects (Appendix I).  A simple effect analysis indicated that both the saline and L-
NAME groups showed a highly significant increase in acoustic startle responses in the 250-
ms post-shock-onset block compared with the 250-ms pre-shock-onset block: saline, 
F=206.47,p<0.000000; L-NAME, F=188.43,p<0.000000. Further analysis of the difference 
scores using a t-test for independent means indicated that the two groups were responding in 
a similar manner, t(14)=0.45,p>0.6. Thus, both the control and L-NAME group exhibited a 
substantial and equivalent increase in movement amplitude as a result of shock presentation.  
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Figure 8. Average movement amplitudes (+ SEM) 250 ms pre- and 250 ms post-shock onset 
as a function of shock reactivity after intra-BSC microinfusion of saline (N = 8) or 0.1µg of 
L-NAME (N = 8). * p < 0.001 relative to baseline movement amplitudes.   
  
3.4.3 Effect of L-NAME on the shock sensitization of the acoustic startle affect  
 
 The dependent measure in this experiment was the animal’s average acoustic startle 
amplitudes in the post-drug / pre-shock block and the post-shock blocks of noise bursts. 
Average acoustic startle responses from the post-shock block were subtracted from acoustic 
startle amplitudes from the post-drug block to give a difference score that was indicative of 
shock enhanced startle responding (Appendix F). If the animals were exhibiting the shock 
sensitization effect then their difference scores should be substantial.  
 Figure 9 shows the average post-infusion and post-shock acoustic startle amplitudes 
and the difference between these two blocks for both the Saline and L-NAME groups. The 
figure illustrates that the acoustic responses of both the saline and L-NAME groups increased 
substantially in the post-shock block compared with the post-infusion block. Thus, both 
groups had considerably large and similar difference scores. 
A 2(Blocks: post-infusion, and post-shock) X2 (Group: saline and L-NAME) repeated 
measures ANOVA with Blocks as the repeated factor confirmed that there was a significant 
     *         * 
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main effect of Blocks, F(1,14)=58.97,p<0.000002, in the absence of any other significant 
effects (Appendix J). A simple effect analyses revealed that the increase in acoustic startle 
responding in the post-shock block compared with the post-infusion block was highly 
significant for both the control group F=18.02, p<0.0009, and L-NAME group, F=43.76, 
p<0.00002. Moreover, a t-test for independent means showed that the difference scores for 
the saline and L-NAME groups were equivalent, t(14)=-0.09,p>0.9. 
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Figure 9. Mean acoustic startle amplitudes (+SEM) post intra-BSC microinfusions of saline 
(N = 8) or 0.1µg of L-NAME (N = 8), and post-shock. * p <0.001 relative to post-drug startle 
amplitudes.   
 
 
   
          *      * 
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4. Discussion 
4.1 Main findings  
 
Activation of NMDA receptors in the BSC is required for both the consolidation and 
expression of conditioned fear. Additionally, these two processes are thought to be mediated 
by NMDA receptors with different subunits. Those with NR2A subunits are thought to play a 
more predominant role in neurotransmission, and thus the expression of fear; while those 
with NR2B subunits are thought to chiefly underpin fear memory consolidation. However, 
the events downstream of activation of these receptors that subserve either event are not well 
characterised. Signalling via the gas NO could be a significant mediatory event. The enzyme 
responsible for the synthesis of NO, nNOS, can associate with either receptor type, and is 
ultimately activated by the calcium influx through activated NMDA receptors. Most 
importantly, nNOS is highly concentrated in the lateral component of the BSC, the 
neuroanatomical area that plays the most crucial role in the molecular underpinnings of 
conditioned fear. It was, therefore, hypothesised that NO could significantly subserve NMDA 
receptor associated processes in the BSC.  
This current study sought to determine whether NO signalling in the BSC plays a 
significant role in during the consolidation and expression of conditioned fear, specifically 
when the CS is visual and FPS is used to examine learned fear expression. The results 
indicated that firstly, intra-BSC microinfusions of 1.0 or 0.1µg of L-NAME prior to fear 
conditioning severely impaired the capacity of the animals to condition to a light-CS. 
Secondly, intra-BSC microinfusions of 0.1 µg of L-NAME, the smallest and most effective 
dosage used in the fear conditioning experiment, impaired the expression of learned fear. 
Conversely, intra-BSC microinfusions of 0.1 µg did not effect shock enhanced acoustic 
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startle responding. Further examination of some possible confounds revealed that L-NAME 
microinfused into the BSC did not affect baseline acoustic startle responding. Thus, the 
results from the fear expression experiment cannot be attributed to a sensiomotor deficit 
induced by the drug. Finally, intra-BSC infusions of L-NAME did not modify the animal’s 
perception of footshock. Therefore, the results from the fear conditioning experiment cannot 
be attributed to the animals not perceiving shock in a normal manner during the conditioning 
procedure. Overall, this current study is the first of its kind to illustrate that NO signalling is 
required for processes associated with conditioned fear, specifically when the CS is visual 
and fear is assessed using FPS. Below, the significance of these findings with regards to the 
relevant literature is discussed.  
4.2 The fear conditioning study  
 
The results of this study indicated that NO signalling in the BSC is required for the 
animals to condition to a light CS. Moreover, because the animals were capable of perceiving 
unconditioned fear, as illustrated by the results of the shock sensitization experiment, the 
results of this study illustrate that NO signalling in the BSC is required for animals to 
associate the light-CS with a fear provoking US, rather than a deficit in emotional responding 
during the conditioning procedure. This finding is consistent with the fact that NO plays a 
significant role during the acquisition and consolidation of other forms of learning (Bohme, 
1993; Calixto, 2001; Cobb, 1995; Holscher, 1996; Meyer, 1998; Samama, 1999; Yamada, 
1995; Zou, 1998). In regards to fear conditioning, one other study using a tone-CS and 
defensive freezing has reported a similar finding (Schafe, 2005). Taken together the results of 
these studies indicate that NO signalling in the BSC mediates the ability of a CS to acquire 
the fear-provoking properties of the US.  
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4.3 The expression of learned fear study 
 
Unlike defensive freezing (Schafe 2005) inhibiting the synthesis of NO impaired the 
expression of learned fear when examined using FPS. Given that the animals were able to 
express unconditioned fear when L-NAME was microinfused into the BSC these results can 
be attributed to a deficit in memory recall rather than emotional responding. Thus, it is 
reasonable to conclude that in addition to its important role in fear conditioning, NO 
synthesis is required for the recall of a conditioned fear memory when the CS is visual.  
4.4 The shock sensitization study 
 
 This experiment revealed that NO signalling is not required for the expression of 
unconditioned fear. Because NO is synthesised as a result of NMDA receptor activation, this 
study supports the recent finding that the NMDA receptor antagonist AP5 does not effect the 
shock sensitization of the acoustic startle effect (Van Nobelen 2006). Furthermore, as 
discussed above, the results of this study indicate that the animals were able to express 
unconditioned fear when NO synthesis was inhibited in the BSC, thus the results of the fear 
conditioning and fear expression experiments can be attributed to a deficit in memory 
associated processes rather than emotional responding. Taken together these studies indicate 
that NO synthesis is required for processes specifically associated with conditioned fear 
rather than unconditioned fear.  
4.5 Limitations  
 
This research would have been improved if it had demonstrated the animals from the 
fear conditioning experiment were in fact capable of learning. In the same manner, it would 
have been advantageous to show that the animals from the fear expression experiment were 
able to express conditioned fear. This would illustrate that the mechanical damage caused by 
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cannulae implantation did not result in the behavioural deficits. One way to address these 
issues is by counteracting the effect of L-NAME by microinfusing the nNOS agonist L-
arginine into the BSA simultaneously. This is a common manipulation used by past 
researchers to ascertain whether the NO signalling pathway was indeed manipulated during 
their experimental procedures. Thus, this precautionary measure would ensure that the 
animals had the capacity to learn or express fear, but would also demonstrate that the NO 
signalling pathway was, undoubtedly, manipulated in this experiment. However, given that 
the control animals were capable of conditioning or expressing conditioned fear, and that L-
NAME microinfusion into the BSC only affected behaviours that are known to require 
NMDA receptor activation, specifically fear conditioning and expression; it seems plausible 
that the NO signalling pathway was examined in this current study and it was, indeed, its 
manipulation that resulted in the memory impairments. Nonetheless, to be certain that this is 
in fact the case, this additional measure could be included in subsequent experiments.  
4.6 Future research and perspectives  
 
Future studies will need to examine precisely how NO signalling contributes to the 
formation of a fear memory. More specifically, pre-conditioning drug infusions, as was 
employed in this study, effect both the acquisition and consolidation of learned fear. Post 
conditioning drug infusions, on the other hand, specifically no more than six hours after the 
procedure, target processes that occur during the consolidation phase of memory formation. 
More specifically, over the hours post fear conditioned the cell signalling cascades that 
eventuate in memory consolidation are in progress (Rodrigues 2004). Thus, it may be 
possible to determine whether NO signalling is indeed required for the consolidation of 
learned fear by infusing a nNOS antagonist into the BSC at successive time points after the 
conditioning procedure. Thus, if nNOS activation over the minutes or hours after 
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conditioning significantly contributes to memory consolidation this manipulation will reveal 
its contribution and the time period of its involvement. However, if the synthesis of NO is 
transient specifically occurring during the conditioning procedure, whereby NO works 
upstream of many of the cell signalling cascades that lead to memory consolidation by 
initiating such events, post-conditioning infusions of a nNOS antagonist may not have an 
effect. Nonetheless, future research of this manner would undoubtedly contribute to 
understanding precisely how NO subserves memory formation.   
The results of the fear expression experiment, however, do allude to the possibility 
that NO signalling simply contributes to routine neurotransmission in a manner that could 
account for the impaired fear conditioning. Indeed, in other brain areas, NO is able to 
increase cellular excitation by attenuating GABAergic inhibition, and augmenting the 
extracellular concentration of the catecholamines and glutamate (Fleckenstein, 1997; 
Guevara-Guzman, 1994; Kaye, 2000; Kiss, 2000; Lander, 1995; Lonart, 1993, 1992; Lu, 
1999; Meffert, 1996; Meffert, 1994; Ohkuma, 2001; Prast, 2001; Robello, 1996; Segovia, 
1994; Wall, 2003; Wexler, 1998; Yun, 1998; Zarri, 1994). NO’s ability to modulate these 
neurochemicals may contribute to fear memory retrieval. Therefore, perhaps NO signalling 
simply subserves a general increase in excitatory tone in the amygdala that is crucial for the 
formation, or more specifically the acquisition, of a fear memory, without affecting the 
cellular machinery specifically required for memory consolidation. Thus, in addition to the 
post-conditioning drug infusions discussed above, future research could include examining 
whether NO was able to activate the cellular components required for fear memory 
consolidation.  
Fear memory consolidation requires de novo protein synthesis, an event that requires 
the activation of the ERK signalling pathway and CREB (Bailey, 1999; Josselyn, 2001; 
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Schafe, 2000, 1999). Research concerning brain areas outside of the amygdala has revealed 
that NO signalling plays a key role activating both these cellular components (Lander, 1995; 
Lu, 1999; Yun, 1998). More specifically, NO is able to activate Ras, which, in turn, activates 
the ERK transduction pathway. Interestingly, Ras in located at both the pre and postsynaptic 
membrane, and ERK signalling in both the pre and postsynaptic cell is required for memory 
consolidation. Thus, given NOS ability to act as a retrograde transmitter it seems probable 
that NO can initiate ERK signalling in both cells as a result of fear conditioning. 
Furthermore, NO is known to facilitate CREB activation in hippocampal cells via the NO-
sGC-cGMP-PKG pathway. Perhaps NO worked in a similar manner in the BSC. Therefore, 
future research will need to examine whether NO did, in fact, activate, or at least contribute 
to the activation, of ERK and CREB. Such research findings will also help to determine the 
precise role played by nitric oxide in the formation of a fear memory, and would 
consequently contribute to understanding the role played by the NMDA receptor in 
conditioned fear.  
Given that NO signalling is a consequence of NMDA receptor activation, the findings 
of this study support research that has demonstrated that NMDA receptor is required for both 
fear conditioning and the expression of conditioned fear, probably mediated by receptors with 
NR2B and NR2A subunits respectively (Blair, 2001; Fendt, 2001; Lee, 2001; Lindquist, 
2004; Maren, 1996; Rodrigues, 2002) Therefore, the results of his study indicate that NMDA 
receptor activation is a crucial requirement of fear memory expression. However, NMDA 
receptor activation during the expression of conditioned fear does not appear to simply 
subserve routine neurotramission; it also required for the animal to learn new information 
about the CS. For example, activation of the NMDA receptor in the BSC is required for fear 
memory extinction and second order fear conditioning (Davis, 2002; Gewirtz, 1997; Lee, 
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1998). Fear extinction occurs when the animal is repetitively exposed to the CS free of the 
US. As a result, the animal relearns not to fear the CS. Second order fear conditioning, on the 
other hand, occurs when a fear conditioned animal is presented with the CS paired with 
another CS (CS2). As a result the animal learns to fear CS2 because it associates it with the 
CS previously paired with the US. The interesting point here is that CS2 essentially becomes 
associated with the US even though it was never explicitly paired with the noxious stimulus. 
Future research concerning the role of NO signalling in the BSC could examine whether the 
gas is an important intermediate step in the formation of these additional NMDA dependent 
memories. However, findings from such research would still raise the question of whether 
NO mediates its effects by subserving routine neurotransmission or memory consolidation. 
Given, the manner in which NO acts in brain areas outside of the amygdala, and the fact that 
it can associate with NMDA receptors with either NR2A or NR2B subunits, it is possible that 
it mediates both processes concurrently.   
Nitric oxide signalling in the amygdala could link fear memory recall and memory 
consolidation together. More specifically, during the initial formation of a fear memory, NO 
synthesis could significantly, and simultaneously, contribute to fear conditioning in two 
ways. Firstly, it could enhance cellular excitation facilitating excitatory neurotransmission, 
ensuring that the BSC is adequately excited to a level required for memory consolidation. 
Secondly, it could activate, or at least significantly prime, the cellular machinery required for 
memory consolation. Later, NO synthesis during the expression of conditioned fear could 
also serve two simultaneous mechanisms. Firstly, it could significantly facilitate cellular 
excitation thus insuring that the fear memory is easily recalled. Secondly, it could modulate 
processes required for memory consolidation thus facilitating new learning. Consequently, 
additional or new information about the recalled memory could be easily acquired, as is seen 
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during fear extinction and second order fear conditioning. Thus, because memory about an 
event or stimulus is subject to change, with new information being added to the existing 
memory with experience, it would seem reasonable to conclude that recall of a previously 
consolidated fear memory would concurrently prime new learning about the fearful event. 
Both process could be subserve by NO signalling, thus eliminating unnecessary signalling 
redundancy during two processes that are so closely related. The above proposition could still 
be consistent with the suggestion that NMDA receptors with NR2A and NR2B subunits 
predominantly mediate neurotransmission associated with conditioned fear and fear memory 
consolidation respectively. Other events downstream of activation of either receptor, or the 
characteristics of receptor activation, could subserve this processing distinction. Though, if 
NO did act in this manner there would be some degree in overlap in the functioning of each 
receptor. This, however, could help to explain why NMDA receptor activation, a process that 
is so intimately tied with memory formation, is also required for the recall of a fear memory. 
As mentioned above, however, future research concerning the precise consequences of NO 
signalling in the BSC is required in order to ascertain whether this is indeed how NO acts in 
this complex.  
4.7 General conclusions  
 
The BSC of the amygdala is a key structure involved in fear conditioning. The 
NMDA receptor within this complex has been implicated in both the consolidation and 
expression of conditioned fear. This study has demonstrated that the gas NO is a crucial 
intermediate step in between glutamatergic mediated activation of the receptor and both these 
processes. That is, this study is the first of its kind to illustrate the importance of NO 
signalling during processes associated with conditioned fear. It therefore makes a new and 
important contribution to the research area concerning the molecular underpinnings of 
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learned fear in the amygdala. Although this study did not demonstrate how NO mediates its 
effects it nonetheless highlights a number of areas for future research.  
4.7.1 Clinical implications  
 
 The finding that NO signalling contributes significantly to both the consolidation and 
expression of conditioned fear may help to clarify the molecular underpinning of 
psychological disorders associated with exaggerated fear and anxiety. Indeed, research 
concerning the fear related disorders schizophrenia and chronic stress has reported that NO 
signalling may be involved (Krukoff, 1997; Salum, 2006; Yao, 2004). In the case of 
schizophrenia, this is appropriate when considering that the NMDA receptor has been 
implicated in this disorder (Coyle, 2004). Thus, this research may illustrate a component of 
how NO may play a role in such fear associated disturbances. Overall, the current study 
provides new details concerning the molecular bases of fear processing and illustrates the 
significant role played by NO in mediating amygdaloid activity associated with conditioned 
fear.  
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Appendix A 
Individual fear potentiated acoustic startle scores for animals in the fear conditioning 
experiment. The table shows individual average acoustic startle scores, for the noise-alone 
trials, noise + light trials, and the difference between these two blocks for all three groups. 
Group means are depicted in bold.  
 
 
Saline group 
5 noise-alone   5 light-plus-noise   Difference 
 
 
118.4     422.4    304 
227.2     250.8    23.6 
267.2     610.8    343.6 
95.4     242.2    146.8 
143.8     384.6    240.8 
255.8     632.2    376.4 
170     156.6    -13.4 
 
182.54                                                385.66                                     251.66                      
 
 
 
 
 
1.0 µg of L-NAME group  
5 noise-alone   5 light-plus-noise   Difference 
 
 
398     537.2    139.2 
234     117.8    -116.2 
118.4     193.2    74.8 
167.2     41.4    -125.8 
163.6     314.4    150.8 
156.2     275.6    119.4 
120.4     142    21.6 
 
193.97                                                 231.66                                    37.68         
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Appendix A continued  
 
 
0.1 µg of L-NAME group  
5 noise-alone   5 light-plus-noise   Difference
 127.8     210.2    82.4 
226.2     274.6    48.4 
137.4     225.6    88.2 
234.2     359    124.8 
437.4     219    -218.4 
454.6     403.2    -51.4 
 
251.66                                      278.31                                    26.66  
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Appendix B 
 
 
2X3 repeated-measures Analysis of variance for the fear conditioning experiment 
Blocks (average noise alone and noise + light acoustic startle amplitudes) X Group (saline, 
1.0, 0.1µg of L-NAME).  
  
Source of   Sum of  DF Mean  F  PROB 
Variation  Squares  Square   
 Drug   38121  2 19061  0.7756  0.475204 
Error   4423  18 24574   
Blocks   83456  1 83456  9.5079  0.006407 
Blocks X Drug 68396  2 384198 3.8961  0.039270 
Error   157995 18 8778 
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Appendix C 
 
One-way Analysis of Variance for the fear conditioning experiment 
Difference scores (average noise-alone acoustic startle amplitudes subtracted from the 
average noise + light acoustic startle amplitudes) against Group (saline, 1.0, 0.1µg of L-
NAME) 
 
Source of   Sum of  DF Mean  F  PROB 
Variation  Squares  Square   
 Group   136.792.5 2 68396.3 3.896101 0.039270 
Error   3159909.9 18 17555.1 
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Appendix D 
 
 
Individual FPS scores for animals in the fear expression experiment. The table shows 
individual average acoustic startle scores, for the noise-alone trials, noise + light trials, and 
the difference between these two blocks for both groups. Group means are depicted in bold. 
  
Saline group 
5 noise-alone   5 light-plus-noise   Difference 
 
 
259     414.8    155.8 
116.4     228.6    112.2 
230.8     501.6    270.8 
261.2     178.4    -82.8 
77.2     207.2    130 
241.6     262.2    20.6 
190.6     480.6    290 
 
196.68                                                  324.77                                     128.09 
  
 
 
 
 
L-NAME group 
5 noise-alone   5 light-plus-noise   Difference 
  
215.4     227.2    11.8 
299.8     273.8    -26 
108.2     130.2    22 
249.6     267.4    17.8  
321     273.4    -47.6 
153.4     206.6    53.2 
 
224.57                                                  229.77                                     5.2 
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Appendix E 
 
2X2 repeated-measures analysis of variance for the fear expression experiment  
Blocks (average noise-alone and noise + light acoustic startle amplitudes) X Group (Saline 
and L-NAME) 
 
Source of   Sum of  DF Mean  F  PROB 
Variation  Squares  Square   
 Group   7278  1 7278  0.5762  0.463773 
Error   138954 11 12632 
Blocks   28697  1 28697  5.7299  0.035626 
Blocks X Drug 24394  1 24394  4.8706  0.049482 
Error   55092  11 5008 
 
  
80 
 
Appendix F  
 
Individual acoustic startle amplitudes for animals in the shock sensitization of the 
acoustic startle experiment. The table shows individual average acoustic startle scores, pre-
drug, post-drug/pre-shock, post shock, and the difference between the pre-drug and post-drug 
blocks (difference), and the difference between post-drug/pre-shock and post-shock blocks 
(sensitization) for both groups. Group means are depicted in bold. 
 
  
             Saline group  
Pre-drug  Post-drug  Difference       Post-shock      Sensitization 
 
 
218.6  223.6  5       285.9  62.3 
206.8  322.2  115.4       486.6  164.4 
218.7  298.5  79.8       367   68.5 
238.2  400  161.8       559.2  159.2 
213.1  295.6  82.5                  460.8  165.2 
224.5  261.9  37.4       210.1  -51.8 
152.9  196.6  43.7       402.2  205.6 
341.6  305.8  -35.8       472.2  166.4 
            226.8               288.03              62.25                    405.5                      117.48  
  
 
 
           
  
L-NAME group 
Pre-drug  Post-drug  Difference       Post-shock      Sensitization 
     277.2  290.5  13.3        503.8  213.3 
 141.9  319  177.1        425.3  106.3 
 165.4  123.8  -41.6        320.3  196.5 
 234.6  235.7  1.1        394.8  158.8  
 156.3  360.8  204.5        581.1  220.3 
 276.5  251.6  -24.9        570.9  319.3 
 529.9  269.6  -260.3        371.4  101.8 
 406.8  393.8  -13        542.3  148.5 
             273.58              280.6               7.03                      405.5                      183.1 
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Appendix G 
 
2X2 repeated-measures Analysis of variance for the shock sensitization experiment. 
Blocks (average acoustic startle amplitudes pre-drug and post-drug) X Group (saline and L-
NAME) 
 
Source of   Sum of  DF Mean  F  PROB 
Variation  Squares  Square   
 Drug   3097  1 3097  0.3147  0.583687 
Error   137775 14 9841 
Blocks   9316  1 9316  1.5295  0.236526 
Blocks X Drug 5875  1 5875  0.9646  0.342695 
Error   85271  14 6091 
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Appendix H 
 
Individual movement amplitudes during assessment of shock reactivity for animals 
from the shock sensitization experiment. The table shows individual average movement 
amplitude 250ms pre shock onset, 250ms post shock onset, and the difference between these 
two blocks (shock reactivity) for both groups. Group means are depicted in bold.  
  
                Saline group  
    250ms pre shock onset       250ms post shock onset       Shock reactivity 
  
 25.1    784.4    759.3 
  55.4    860.9    805.5 
 25.6    951.6    926 
 30.7    973.6    942.9 
 120.7    628.7    508 
 95.1    1141.8    1046.7 
 40.6    769.1    755.5 
 59.6    865.7    806.1 
 
            56.6                                         875.35                                      818.75 
 
 
 
 
 
 
                        L-NAME group  
    250ms pre shock onset       250ms post shock onset       Shock reactivity 
        
 26.1    916    889.9 
 32.7    827.5    794.8  
 22.4    571.5    549.1 
 19.6    1067.1    1047.5 
 39.2    683.4    644.2 
 36.2    932    895.8 
 34.2    794.9    760.7 
 22.1    697.4    675.3 
             29.06                                       811.23                                     782.17 
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Appendix I 
 
 
2X2 repeated-measures analysis of variance for the shock sensitization experiment. 
Blocks (movement amplitude 250ms pre shock-onset and 250ms post shock onset) X Group 
(Saline and L-NAME) 
 
Source of   Sum of  DF Mean  F  PROB 
Variation  Squares  Square   
 Drug   16804  1 16804  1.4042  0.255745 
Error   167536 14 11967   
Blocks   5125842 1 5125842 394.6972 0.000000 
Blocks X Drug 2677  1 2677  0.2062  0.656757 
Error   181815 14 12987   
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Appendix J 
 
2X2 repeated-measures analysis of variance for the shock sensitization experiment. 
Blocks (average movement amplitudes post-drug/pre-shock and post-shock) X Group (Saline 
and L-NAME) 
 
Source of   Sum of  DF Mean  F  PROB 
Variation  Squares  Square   
 Drug   5156  1 5156  0.3741  0.550578 
Error   192958 14 13783   
Blocks   180691 1 180691 58.9676 0.000002 
Blocks X Group 8613  1 8613  2.8109  0.115803 
Error   42899  14 3064   
  
  
85 
     
